October 2, 2015
Vernalis Acquires U.S. Rights to Moxatag
Vernalis plc has announces that it has acquired the US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (“Pragma”).
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 2, 2015
Sanofi: Genzyme Opts into Alnylam’s ALN-AT3 Hemophilia Program
Sanofi and its subsidiary Genzyme have announced that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.
October 2, 2015
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Novartis company has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) – a tumor necrosis factor alpha (TNF-alpha) inhibitor.
October 1, 2015
FDA Advises: Don’t use NATUREAL nor and Ultimate Herbal Slimcap weight loss programes
The Food and Drug Administration (FDA) is advising consumers not to purchase or use NATUREAL, a product promoted and sold for weight loss.
October 1, 2015
Bayer CropScience: Horticulture Symposium in Puerto Vallarta, Mexico
Bayer has announced that from September 30th to October first, Bayer CropScience is hosting over 175 industry professionals from over 15 different countries at its Horticulture Symposium in Puerto Vallarta, Mexico.
October 1, 2015
NIH totals $85M for BRAIN initiative in 2015
The National Institutes of Health has shared its second wave of grants to support the goals of the Brain Research through…
October 1, 2015
Allergen buys Kythera Biopharmaceuticals for $2.1B
Allergan has completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel…
October 1, 2015
FDA approves Allergan’s Juvederm ultra XC
Allergan plc has announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market Juvederm ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21.
October 1, 2015
Teva’s Phase 2B Migraine Program
Teva Pharmaceutical Industries Ltd., has announced that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b…